OBJECTIVES:  To evaluate the impact of SJIA on the caregiver’s work productivity and the child’s schooling. METHODS:  As part of an international study to assess the burden of SJIA on the caregiver and patient, from a caregiver’s perspective, caregiver’s work productivity (using the work productivity and activity impairment questionnaire (WPAI) and impact on patients schooling (using tailored questions) were assessed. Caregivers indicated change in work commitments due to their child’s SJIA and how frequently it caused them to miss work or for their child or siblings to miss school. RESULTS: Sixty-one biologic treated patients participated (12 anakinra, 25 canakinumab, 24 tocilizumab). Mean age at diagnosis and survey completion was 6.4 and 11.3 years, respectively. 77% of caregivers were employed (full or part time), however 36% had reduced their number of working hours or stopped working due to their child’s SJIA. SJIA related appointments were the main cause of a caregiver missing work, in the past two months (57%). Employed caregivers had missed a mean 2.8 hours of work in the past seven days due to their child’s SJIA, equating to approximately 25 working days annually. Caregiver’s mean absenteeism score based on WPAI, was 10% and mean presenteeism score (reduced on-the-job effectiveness) was 11%, equivalent to a productivity loss of 27.5 work days. In the two months prior to survey completion, a mean 2.9 school days were missed by patients due to their SJIA. Assuming a 5-day school week and 36 school weeks per year, this equated to 10% yearly schooling loss. SJIA caused patients’ siblings to miss a mean 0.3 days of school in the past two months. CONCLUSIONS: SJIA families experience reduced school and work productivity. There is a need for effective therapeutic interventions which are not burdensome and limit disruption on SJIA families’ lives.